RGNX Stock Analysis: Regenxbio | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 687m USD | 12M Return: 75.9% | Charts, Fundamentals & Technical Analysis

Ophthalmology, Muscular Dystrophy, Rare Diseases, Gene Therapy
Total Rating 35
Safety 35
Buy Signal 0.12
Biotechnology
Industry Rotation: +31.1
Market Cap: 687M
Avg Turnover: 17.8M
Risk 3d forecast
Volatility118%
VaR 5th Pctl19.2%
VaR vs Median-1.13%
Reward TTM
Sharpe Ratio1.02
Rel. Str. IBD89.5
Rel. Str. Peer Group58.3
Character TTM
Beta2.158
Beta Downside1.577
Hurst Exponent0.571
Drawdowns 3y
Max DD78.42%
CAGR/Max DD-0.12
CAGR/Mean DD-0.19
EPS (Earnings per Share) EPS (Earnings per Share) of RGNX over the last years for every Quarter: "2021-06": -1.36, "2021-09": -1.37, "2021-12": 6.67, "2022-03": -1.79, "2022-06": -1.58, "2022-09": -1.75, "2022-12": -1.38, "2023-03": -1.53, "2023-06": -1.66, "2023-09": -1.41, "2023-12": -1.43, "2024-03": -1.34, "2024-06": -1.05, "2024-09": -1.17, "2024-12": -1.01, "2025-03": 0.12, "2025-06": -1.38, "2025-09": -1.2, "2025-12": -1.3, "2026-03": -1.72,
Last SUE: -1.20
Qual. Beats: -2
Revenue Revenue of RGNX over the last years for every Quarter: 2021-06: 22.035, 2021-09: 30.773, 2021-12: 398.655, 2022-03: 22.218, 2022-06: 32.649, 2022-09: 26.512, 2022-12: 31.345, 2023-03: 19.138, 2023-06: 19.977, 2023-09: 28.914, 2023-12: 22.213, 2024-03: 15.622, 2024-06: 22.295, 2024-09: 24.197, 2024-12: 21.214, 2025-03: 89.012, 2025-06: 21.359, 2025-09: 29.733, 2025-12: 30.337, 2026-03: 6.393,
Rev. CAGR: 19.01%
Rev. Trend: 53.4%
Last SUE: -2.08
Qual. Beats: -2

Warnings

Interest Coverage Ratio Critical
Altman Z'' In Financial Distress Zone
Overextended 1w

Tailwinds

Rs Leader

Seasonality 10.5 years of data

Jan -1.8% 23
Feb +0.1% 0
Mar +0.4% 2
Apr +4.2% 24
May -5.6% 15
Jun +13.9% 47
Jul -8.1% 3
Aug -2.7% 34
Sep +1.6% 6
Oct -7.8% 25
Nov +4.5% 22
Dec +0.5% 8

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: RGNX Regenxbio

REGENXBIO Inc. (RGNX) is a U.S.-based, clinical-stage biotechnology company developing gene therapies that use its proprietary NAV Technology Platform, an adeno-associated virus (AAV) gene delivery system, to deliver functional genes to cells with genetic defects. Its pipeline includes ABBV-RGX-314 for wet age-related macular degeneration and diabetic retinopathy, RGX-202 for Duchenne muscular dystrophy, RGX-121 for mucopolysaccharidosis type II (Hunter syndrome), and RGX-111 for mucopolysaccharidosis type I.

The company is headquartered in Rockville, Maryland, was incorporated in 2008, and operates a dual business model: it develops internal gene therapy candidates while also licensing its NAV platform to other biotech and pharmaceutical partners. Notable collaborations include a development and license agreement with AbbVie for ABBV-RGX-314 and a partnership with Nippon Shinyaku for RGX-121 and RGX-111 outside the United States. As a clinical-stage biotech, REGENXBIO is not yet generating commercial product revenue, making collaboration income, milestone payments, and capital markets funding key financial drivers typical of the sector.

Headlines to Watch Out For
  • ABBV-RGX-314 wet AMD pivotal trial data readout approaches
  • AbbVie collaboration milestones critical to extending cash runway
  • Duchenne RGX-202 gene therapy competes against Sareptas Elevidys
Piotroski VR-10 (Strict) 0.5
Net Income: -290.0m TTM > 0 and > 6% of Revenue
FCF/TA: -0.71 > 0.02 and ΔFCF/TA -49.08 > 1.0
NWC/Revenue: 131.4% < 20% (prev 131.8%; Δ -0.36% < -1%)
CFO/TA -0.68 > 3% & CFO -233.8m > Net Income -290.0m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.62 > 1.5 & < 3
Outstanding Shares: last quarter (52.4m) vs 12m ago 1.93% < -2%
Gross Margin: -0.14% > 18% (prev 76.54%; Δ -76.67% > 0.5%)
Asset Turnover: 21.09% > 50% (prev 31.92%; Δ -10.83% > 0%)
Interest Coverage Ratio: -5.42 > 6 (EBIT TTM -244.9m / Interest Expense TTM 45.1m)
Altman Z'' -13.26
A: 0.34 (Total Current Assets 186.5m - Total Current Liabilities 71.1m) / Total Assets 341.9m
B: -3.56 (Retained Earnings -1.22b / Total Assets 341.9m)
C: -0.59 (EBIT TTM -244.9m / Avg Total Assets 416.4m)
D: 0.07 (Book Value of Equity 21.1m / Total Liabilities 320.8m)
Altman-Z'' = -13.26 = D
Beneish M -3.32
DSRI: 1.02 (Receivables 10.9m/19.2m, Revenue 87.8m/156.7m)
GMI: 1.00 (fallback, negative margins)
AQI: 1.03 (AQ_t 0.02 / AQ_t-1 0.02)
SGI: 0.56 (Revenue 87.8m / 156.7m)
TATA: -0.16 (NI -290.0m - CFO -233.8m) / TA 341.9m)
Beneish M = -3.32 (Cap -4..+1) = AA
What is the price of RGNX shares?

As of July 07, 2026, the stock is trading at USD 14.83 with a total of 3,147,106 shares traded. Over the past week, the price has changed by +41.51%, over one month by +141.92%, over three months by +68.52% and over the past year by +75.92%.

Current recommended Stop Loss: 12.70 (which is 14.4% or 2.3 ATR below the current price).

Is RGNX a buy, sell or hold?

Regenxbio has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy RGNX.

  • StrongBuy: 6
  • Buy: 5
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the RGNX price?
Analysts Target Price 24.4 64.3%
Regenxbio (RGNX) - Fundamental Data Overview as of 04 July 2026
Market Cap USD = 686.5m (686.5m USD * 1.0 USD.USD)
P/S = 7.8175
P/B = 32.0995
P/EG = 0.26
Revenue TTM = 87.8m USD
EBIT TTM = -244.9m USD
EBITDA TTM = -229.3m USD
Long Term Debt = 63.2m USD (estimated: total debt 71.1m - short term 7.87m)
Short Term Debt = 7.87m USD (from shortTermDebt, last quarter)
Debt = 71.1m USD (from shortLongTermDebtTotal, last quarter) (leases 71.1m already included)
Net Debt = -21.1m USD (calculated: Debt 71.1m - CCE 92.1m)
Enterprise Value = 665.5m USD (686.5m + Debt 71.1m - CCE 92.1m)
Interest Coverage Ratio = -5.42 (Ebit TTM -244.9m / Interest Expense TTM 45.1m)
EV/FCF = -2.74x (Enterprise Value 665.5m / FCF TTM -242.5m)
FCF Yield = -36.44% (FCF TTM -242.5m / Enterprise Value 665.5m)
 FCF Margin = -276.1% (FCF TTM -242.5m / Revenue TTM 87.8m)
 Net Margin = -330.2% (Net Income TTM -290.0m / Revenue TTM 87.8m)
 Gross Margin = -0.14% ((Revenue TTM 87.8m - Cost of Revenue TTM 87.9m) / Revenue TTM)
Gross Margin QoQ = -73.22% (prev 80.46%)
Tobins Q-Ratio = 1.95 (Enterprise Value 665.5m / Total Assets 341.9m)
 Interest Expense / Debt = 63.53% (Interest Expense 45.1m / Debt 71.1m)
 Taxrate = 21.0% (US federal default 21%)
NOPAT = -193.4m (EBIT -244.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.02 (Total Current Assets 186.5m / Total Current Liabilities 92.3m)
Debt / Equity = 3.37 (Debt 71.1m / totalStockholderEquity, last quarter 21.1m)
 Debt / EBITDA = 0.09 (negative EBITDA) (Net Debt -21.1m / EBITDA -229.3m)
 Debt / FCF = 0.09 (negative FCF - burning cash) (Net Debt -21.1m / FCF TTM -242.5m)
 Total Stockholder Equity = 124.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -69.65% (Net Income -290.0m / Total Assets 341.9m)
RoE = -232.5% (Net Income TTM -290.0m / Total Stockholder Equity 124.7m)
 RoCE = -130.3% (out of range, set to none) (EBIT -244.9m / Capital Employed (Equity 124.7m + L.T.Debt 63.2m))
 RoIC = -70.53% (negative operating profit) (NOPAT -193.4m / Invested Capital 274.3m)
 WACC = 12.30% (E(686.5m)/V(757.6m) * Re(13.57%) + (debt cost/tax rate unavailable))
Discount Rate = 13.57% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 100.00 | Cagr: 8.10%
 [DCF] Fair Price = unknown (Cash Flow -242.5m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.20 | # QB: -2
Revenue Correlation: 53.42 | Revenue CAGR: 19.01% | SUE: -2.08 | # QB: -2
EPS current Quarter (2026-06-30): EPS=0.12 | Chg30d=-65.32% | Revisions=-17% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-1.22 | Chg30d=+17.37% | Revisions=+38% | Analysts=7
EPS current Year (2026-12-31): EPS=-2.82 | Chg30d=+0.88% | Revisions=-50% | GrowthEPS=+24.9% | GrowthRev=+39.6%
EPS next Year (2027-12-31): EPS=-2.57 | Chg30d=-2.15% | Revisions=+25% | GrowthEPS=+8.8% | GrowthRev=+4.0%
[Analyst] Revisions Ratio: -11% (up=7, down=9)